Terms: = Ovarian cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Clinical Outcome
34 results:
1. clinical outcome and Morphology-Based Analysis of p53 Aberrant and Mismatch Repair Protein-Deficient ovarian Clear Cell Carcinoma and Their Association With p16, HER2, and PD-L1 Expression.
Wilkins R; Lin LH; Xia R; Shiomi T; Zamuco RD; Shukla PS
Am J Clin Pathol; 2023 Nov; 160(5):466-476. PubMed ID: 37415414
[TBL] [Abstract] [Full Text] [Related]
2. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and ovarian cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract] [Full Text] [Related]
3. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the Uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse clinical outcomes.
Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
[TBL] [Abstract] [Full Text] [Related]
4. Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer.
Narasimhulu DM; Bews KA; Hanson KT; Chang YH; Dowdy SC; Cliby WA
Gynecol Oncol; 2020 Feb; 156(2):278-283. PubMed ID: 31785863
[TBL] [Abstract] [Full Text] [Related]
5. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
Wang J; Dean DC; Hornicek FJ; Shi H; Duan Z
FASEB J; 2019 May; 33(5):5990-6000. PubMed ID: 30726104
[TBL] [Abstract] [Full Text] [Related]
6. Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial ovarian Carcinoma.
Fridley BL; Dai J; Raghavan R; Li Q; Winham SJ; Hou X; Weroha SJ; Wang C; Kalli KR; Cunningham JM; Lawrenson K; Gayther SA; Goode EL
Cancer Epidemiol Biomarkers Prev; 2018 Sep; 27(9):1101-1109. PubMed ID: 29967001
[No Abstract] [Full Text] [Related]
7. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.
Parra-Herran C; Lerner-Ellis J; Xu B; Khalouei S; Bassiouny D; Cesari M; Ismiil N; Nofech-Mozes S
Mod Pathol; 2017 Dec; 30(12):1748-1759. PubMed ID: 28776572
[TBL] [Abstract] [Full Text] [Related]
8. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.
Gershenson DM; Sun CC; Wong KK
Br J Cancer; 2015 Nov; 113(9):1254-8. PubMed ID: 26484411
[TBL] [Abstract] [Full Text] [Related]
9. clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.
Watkins JL; Thaker PH; Nick AM; Ramondetta LM; Kumar S; Urbauer DL; Matsuo K; Squires KC; Coleman RL; Lutgendorf SK; Ramirez PT; Sood AK
Cancer; 2015 Oct; 121(19):3444-51. PubMed ID: 26301456
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
Siamakpour-Reihani S; Owzar K; Jiang C; Turner T; Deng Y; Bean SM; Horton JK; Berchuck A; Marks JR; Dewhirst MW; Alvarez Secord A
Gynecol Oncol; 2015 Oct; 139(1):23-9. PubMed ID: 26260910
[TBL] [Abstract] [Full Text] [Related]
11. MicroRNAs in endometrial cancers from black and white patients.
Maxwell GL; Shoji Y; Darcy K; Litzi T; Berchuck A; Hamilton CA; Conrads TP; Risinger JI
Am J Obstet Gynecol; 2015 Feb; 212(2):191.e1-10. PubMed ID: 25174797
[TBL] [Abstract] [Full Text] [Related]
12. Septin 9 amplification and isoform-specific expression in peritumoral and tumor breast tissue.
Connolly D; Hoang HG; Adler E; Tazearslan C; Simmons N; Bernard VV; Castaldi M; Oktay MH; Montagna C
Biol Chem; 2014 Feb; 395(2):157-67. PubMed ID: 24127542
[TBL] [Abstract] [Full Text] [Related]
13. Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
Roque DM; Bellone S; English DP; Buza N; Cocco E; Gasparrini S; Bortolomai I; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
Cancer; 2013 Jul; 119(14):2582-92. PubMed ID: 23585021
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer.
Yang C; Lee H; Jove V; Deng J; Zhang W; Liu X; Forman S; Dellinger TH; Wakabayashi M; Yu H; Pal S
PLoS One; 2013; 8(1):e54029. PubMed ID: 23326565
[TBL] [Abstract] [Full Text] [Related]
15. Peritoneal washing cytologic analysis of ovarian serous tumors of low malignant potential to detect peritoneal implants and predict clinical outcome.
Sneige N; Thomison JB; Malpica A; Gong Y; Ensor J; Silva EG
Cancer Cytopathol; 2012 Aug; 120(4):238-44. PubMed ID: 22826172
[TBL] [Abstract] [Full Text] [Related]
16. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon.
Streppel MM; Vincent A; Mukherjee R; Campbell NR; Chen SH; Konstantopoulos K; Goggins MG; Van Seuningen I; Maitra A; Montgomery EA
Hum Pathol; 2012 Oct; 43(10):1755-63. PubMed ID: 22542127
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.
Odunsi K; Matsuzaki J; Karbach J; Neumann A; Mhawech-Fauceglia P; Miller A; Beck A; Morrison CD; Ritter G; Godoy H; Lele S; duPont N; Edwards R; Shrikant P; Old LJ; Gnjatic S; Jäger E
Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5797-802. PubMed ID: 22454499
[TBL] [Abstract] [Full Text] [Related]
18. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
Nick AM; Stone RL; Armaiz-Pena G; Ozpolat B; Tekedereli I; Graybill WS; Landen CN; Villares G; Vivas-Mejia P; Bottsford-Miller J; Kim HS; Lee JS; Kim SM; Baggerly KA; Ram PT; Deavers MT; Coleman RL; Lopez-Berestein G; Sood AK
J Natl Cancer Inst; 2011 Nov; 103(21):1596-612. PubMed ID: 21957230
[TBL] [Abstract] [Full Text] [Related]
19. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
Wong KK; Tsang YT; Deavers MT; Mok SC; Zu Z; Sun C; Malpica A; Wolf JK; Lu KH; Gershenson DM
Am J Pathol; 2010 Oct; 177(4):1611-7. PubMed ID: 20802181
[TBL] [Abstract] [Full Text] [Related]
20. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials.
Farley JH; Tian C; Rose GS; Brown CL; Birrer M; Maxwell GL
Cancer; 2009 Sep; 115(18):4210-7. PubMed ID: 19536873
[TBL] [Abstract] [Full Text] [Related]
[Next]
